InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases FY 2022 Financial, Corporate Report

Dec 14, 2022

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has filed its audited financial statements and is reporting on corporate highlights for the fiscal year ending Aug. 31, 2022. Highlights include the World Intellectual Property Organization publishing TRYPF’s international PCT patent application, which covers the intravenous administration of psilocybin and psilocin. The patent is connected to Tryp’s development of TRP-8803, an intravenous infusion of psilocin designed to significantly reduce the time to onset of the psychedelic state, control the depth and duration of the psychedelic experience, and reduce the overall duration of the intervention to a commercially feasible timeframe. Other highlights include the filing of provisional patents for the use of psilocybin for the treatment of patients with binge eating disorder and for the treatment of patients with fibromyalgia. The report also noted the filing of a provisional patent for crystalline forms of TRP-8803. In addition, Tryp started preparations for a phase 2a trial using TRP-8802 to evaluate psilocybin-assisted therapy among patients with fibromyalgia. “Tryp has continued to execute its multipronged strategy of exploring the clinical utility of psilocybin-assisted psychotherapy, expanding its IP portfolio, and advancing TRP-8803 (IV-infused psilocin), the company’s proprietary and eventual commercial product,” said Tryp Therapeutics CEO Jim Gilligan in the press release. “To that end, Tryp expects to have the interim results from our phase 2a clinical binge eating disorder trial as early as January 2023 and has submitted several provisional patents related to fibromyalgia, binge eating disorder, and co-formers of TRP-8803. Furthermore, the company has completed a series of pharmacology and toxicology programs necessary to advance TRP-8803 into the clinic. With a burgeoning pipeline and a variety of novel and impactful provisional patents in place, we look forward to continuing to execute our business plan in 2023 and beyond.”

To view the full release, visit https://ibn.fm/rqUez

About Tryp Therapeutics Inc.

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) for the potential treatment of eating disorders, chronic pain, and other indications. The company has an ongoing phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida and an upcoming phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Subsequent studies are expected to utilize TRP-8803, which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

More News

US Navy chief urges US lawmakers to strengthen shipbuilding capacity to close gap on China
Nov 17, 2026
US Navy chief urges US lawmakers to strengthen shipbuilding capacity to close gap on China

Acting US Navy Secretary Hung Cao told senators on Tuesday that shipbuilders from allies such as South Korea and Japan could help the United States rebuild its shipyards and narrow China’s lead, as lawmakers pressed him to keep warship construction on American soil. Cao made his remarks in an opening statement at a Senate Committee on Armed Services hearing to confirm his nomination to become the new Secretary of the Navy. The Navy veteran of three decades said the US is in an era of...

Spy or not, Alice Huang was a useful pawn
Nov 17, 2026
Spy or not, Alice Huang was a useful pawn

She might not be a spy after all, but she could have been. That, apparently, is US intelligence’s current assessment of Alice Huang, the microchip siren blamed for bringing down AI titan Jensen Huang. “The US intelligence community is still working to understand the relationship between a Chinese businesswoman who had an affair with [then] Nvidia CEO Jensen Huang and the Chinese government,” CNN reported, citing multiple sources. “The intelligence collected on her to date,” it said, “does not...

Shenzhen summit of Xi, Trump and Putin was Brazil’s Lula’s idea, Carney claims
Nov 17, 2026
Shenzhen summit of Xi, Trump and Putin was Brazil’s Lula’s idea, Carney claims

Brazilian President Luiz Inacio Lula da Silva came up with the idea for the meeting between US President Donald Trump, Chinese President Xi Jinping and Russian President Vladimir Putin, Canadian Prime Minister Mark Carney said on Monday, days before the three leaders were due to meet in Shenzhen. “He told me yesterday that he had encouraged this meeting to help bring about an end to the war in Ukraine,” Carney told reporters on the sidelines of the Francophonie summit in Phnom Penh. Carney, who...

SC extends conviction stay to Azam Khan's wife & son
Nov 17, 2026
SC extends conviction stay to Azam Khan's wife & son

The Supreme Court has upheld the Allahabad High Court's decision to stay the convictions of Azam Khan and his family. Azam Khan, his wife Tazeen Fatima, and son Abdullah had been convicted in a forged birth certificate case. The family was sentenced to seven years in prison for multiple offenses related to the fraudulent documents.

Cricket: IPL career over, Dhoni unveiled as Chennai team mentor
Nov 17, 2026
Cricket: IPL career over, Dhoni unveiled as Chennai team mentor

The 45-year-old, who captained Chennai to a record five IPL titles and two Champions League Twenty20 crowns, quit international cricket in 2020.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Daily World Feed

Get yourself immersed in engaging topics right here. Daily World Feed is a multi-platform media, providing you latest breaking news straight from the industry.

Sign Up